Novel BCR-ABL1 inhibitor aximini

Aximini, this innovative BCR-ABL1 tyrosine kinase inhibitor, is gradually becoming a new star in the treatment of chronic myelogenous leukemia (CML). Its unique mechanism of action provides new ideas for overcoming the resistance problem of traditional tyrosine kinase inhibitors (TKI).

The root cause of CML lies in the BCR-ABL1 fusion gene. The tyrosine kinase encoded by this gene is the key to driving abnormal proliferation of leukemia cells. By precisely inhibiting the activity of this kinase, Aceminib can effectively block the proliferation and survival pathways of leukemia cells, thereby curbing the progression of the disease.

Compared with traditionalTKI (such as imatinib, nilotinib), aximinib has a unique mechanism of action. It does not target the ATP binding site of the kinase, but focuses on the "myristoyl pocket" of BCR-ABL1 tyrosine kinase. This specific domain is the binding site of aximini. By binding to it, aximini can change the conformation of tyrosine kinase and make it inactive, thus achieving the effect of inhibiting leukemia cells. This novel mechanism of action enables aximini to exhibit excellent efficacy in treating certain drug-resistant mutations.

It is particularly worth mentioning that Asiminib has shown significant therapeutic advantages in the face of common drug-resistant mutations such as T315I mutations. These mutations are often an important reason why CML patients are resistant to most TKI drugs. Aceminib's unique mechanism of action can effectively inhibit the BCR-ABL1 kinase associated with such mutations, opening up new treatment avenues for such patients.

In addition, Aceminib’s selectivity and specificity result in fewer side effects during treatment, helping to improve patients’ quality of life and reduce discomfort caused by treatment. Its unique mechanism of action not only provides new options for the treatment of CML, but also brings hope to drug-resistant patients.